---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-038108"
form_type: "8-K"
ticker: "SVRA"
cik: "0001160308"
company_name: "Savara Inc"
filed_at: "2024-02-16T23:59:59+00:00"
generated_at: "2026-06-06T00:03:48.913705+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Savara enters master services agreement with Fujifilm for molgramostim manufacturing

## Summary
- Agreement covers development and manufacturing services for molgramostim active pharmaceutical ingredient.
- Scope of Work #03 executed for Process Performance Qualification manufacturing campaign.
- Either party may terminate with three months' notice if no scope-of-work activities are in process.
- Termination also allowed for material uncured breach or unforeseen technical issues by Fujifilm.
- Includes standard provisions on confidentiality, intellectual property, liability, and indemnification.

## SEC filing metadata
- accession: 0001193125-24-038108
- form_type: 8-K
- ticker: SVRA
- cik: 0001160308
- company_name: Savara Inc
- filed_at: 2024-02-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1160308/000119312524038108/0001193125-24-038108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1160308/000119312524038108/d775782d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-038108
- JSON: https://secwatch.observer/filing/0001193125-24-038108.json
- Plain text: https://secwatch.observer/filing/0001193125-24-038108.txt

## Key facts
- Material Agreements
  Savara Inc entered into Master Services Agreement with Fujifilm Diosynth Biotechnologies UK Limited, Fujifilm Diosynth Biotechnologies Texas, LLC, and Fujifilm Diosynth Biotechnologies U.S.A., Inc. (collectively, “Fujifilm”) (effective 2024-02-13).
  - Action: entry
  - Counterparty: Fujifilm Diosynth Biotechnologies UK Limited, Fujifilm Diosynth Biotechnologies Texas, LLC, and Fujifilm Diosynth Biotechnologies U.S.A., Inc. (collectively, “Fujifilm”)
  - Effective: 2024-02-13
  source text: On February 13, 2024, Savara Inc. (the “Company”) entered into a Master Services Agreement (the “Agreement”) with Fujifilm Diosynth Biotechnologies UK Limited, Fujifilm Diosynth Biotechnologies Texas, LLC, and Fujifilm Diosynth Biotechnologies U.S.A., Inc. (collectively, “Fujifilm”), pursuant to which Fujifilm will continue to provide development and manufacturing services related to active pharmaceutical ingredient for the Company’s molgramostim product candidate in accordance with the terms of separate scope of work agreements to be entered into by the parties.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1160308/000119312524038108/0001193125-24-038108-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.